Royce & Associates LP Has $394,000 Stake in Ironwood Pharmaceuticals, Inc. $IRWD

Royce & Associates LP lessened its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 40.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 300,619 shares of the biotechnology company’s stock after selling 205,441 shares during the period. Royce & Associates LP owned 0.19% of Ironwood Pharmaceuticals worth $394,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Millennium Management LLC raised its holdings in shares of Ironwood Pharmaceuticals by 186.6% during the 1st quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock worth $9,349,000 after buying an additional 4,140,439 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Ironwood Pharmaceuticals by 147.6% in the second quarter. Acadian Asset Management LLC now owns 6,549,687 shares of the biotechnology company’s stock valued at $4,685,000 after buying an additional 3,904,498 shares in the last quarter. AQR Capital Management LLC boosted its stake in Ironwood Pharmaceuticals by 144.3% in the second quarter. AQR Capital Management LLC now owns 6,165,637 shares of the biotechnology company’s stock valued at $4,422,000 after buying an additional 3,641,762 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Ironwood Pharmaceuticals by 616.3% during the second quarter. Marshall Wace LLP now owns 3,993,557 shares of the biotechnology company’s stock worth $2,875,000 after buying an additional 3,436,036 shares in the last quarter. Finally, Jane Street Group LLC lifted its stake in shares of Ironwood Pharmaceuticals by 740.5% in the 1st quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company’s stock valued at $5,160,000 after acquiring an additional 3,092,475 shares during the last quarter.

Ironwood Pharmaceuticals Trading Down 3.6%

Shares of Ironwood Pharmaceuticals stock opened at $3.49 on Friday. The business has a 50-day moving average price of $4.32 and a two-hundred day moving average price of $2.91. Ironwood Pharmaceuticals, Inc. has a 1-year low of $0.53 and a 1-year high of $5.78. The company has a market cap of $567.75 million, a P/E ratio of 26.85 and a beta of 0.24.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Wednesday, February 25th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.03). Ironwood Pharmaceuticals had a net margin of 8.11% and a negative return on equity of 13.72%. The company had revenue of $47.71 million for the quarter, compared to analyst estimates of $86.10 million. Equities research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on IRWD. Craig Hallum raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 5th. Wells Fargo & Company lifted their target price on shares of Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the stock an “equal weight” rating in a research report on Monday, January 5th. Wall Street Zen lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. Citigroup upgraded shares of Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, January 5th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $3.70 price target on shares of Ironwood Pharmaceuticals in a research note on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $4.93.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.